1. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). (1st July 2014) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Toole, J.; Vieira, A.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 2(2015:Feb.) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study. (15th November 2017) Authors: Bissonnette, R.; Haydey, R.; Rosoph, L.A.; Lynde, C.W.; Bukhalo, M.; Fowler, J.F.; Delorme, I.; Gagné‐Henley, A.; Gooderham, M.; Poulin, Y.; Barber, K.; Jenkin, P.; Landells, I.; Pariser, D.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 3(2018) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. (20th January 2015) Authors: Bissonnette, R.; Maari, C.; Barber, K.; Lynde, C.W.; Vender, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 8(2015:Aug.) Page Start: 1576 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council. (10th March 2016) Authors: Wu, J.J.; Lynde, C.W.; Kleyn, C.E.; Iversen, L.; van der Walt, J.M; Carvalho, A.; Kirby, B.; Bissonnette, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 7(2016:Jul.) Page Start: 1115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. (21st January 2015) Authors: Papp, K.A.; Barber, K.; Bissonnette, R.; Bourcier, M.; Lynde, C.W.; Poulin, Y.; Shelton, J.; Garces, K.; Toole, J.; Poulin‐Costello, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 8(2015:Aug.) Page Start: 1555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Increased expression of IL‐17A and limited involvement of IL‐23 in patients with palmo‐plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. (24th September 2013) Authors: Bissonnette, R.; Nigen, S.; Langley, R.G.; Lynde, C.W.; Tan, J.; Fuentes‐Duculan, J.; Krueger, J.G. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 10(2014:Oct.) Page Start: 1298 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. (3rd February 2021) Authors: Beecker, J.; Papp, K.A.; Dutz, J.; Vender, R.B.; Gniadecki, R.; Cooper, C.; Gisondi, P.; Gooderham, M.; Hong, C.H.; Kirchhof, M.G.; Lynde, C.W.; Maari, C.; Poulin, Y.; Puig, L. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 4(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians' offices. (11th May 2016) Authors: Gupta, A.K.; Gupta, G.; Jain, H.C.; Lynde, C.W.; Foley, K.A.; Daigle, D.; Cooper, E.A.; Summerbell, R.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 9(2016:Sep.) Page Start: 1567 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. (19th April 2017) Authors: Iversen, L.; Lange, M.M.; Bissonette, R.; Carvalho, A.V.E.; van de Kerkhof, P.C.; Kirby, B.; Kleyn, C.E.; Lynde, C.W.; van der Walt, J.M.; Wu, J.J. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 7(2017) Page Start: 1188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗